Nordic Capital-backed Acino signs agreement to acquire Takeda primary care portfolio in key emerging markets

October 15 2019
Nordic Capital-backed Acino signs agreement to acquire Takeda primary care portfolio in key emerging markets Image

Acino and Takeda Pharmaceuticals announced today that they have signed an agreement for Acino to acquire parts of Takeda’s primary care portfolio in selected countries in the Middle East and Africa, and in Ukraine. The acquisition will further strengthen Acino’s position in these important regions.

Acino, a Nordic Capital backed company, will acquire approximately 30 products from Takeda’s primary care portfolio in selected countries in the Middle East and Africa, and in Ukraine from Takeda, subject to conditions.

‘This agreement strengthens our presence in our core emerging markets where we have established ourselves as a leading high-quality pharmaceutical provider’, says Steffen Saltofte, CEO of Acino. ‘It will allow us to expand our offering in both key therapeutic areas and key markets; and ensure that patients in emerging markets will have continued access to a broad range of high-quality affordable medicines as part of the Acino portfolio’.

As part of this acquisition, Acino will acquire the rights to selected pain management, gastroenterology, cardiovascular and respiratory products from Takeda’s prescription pharmaceutical and OTC portfolio. The agreement will enable Acino to reinforce its position in the following key markets United Arab Emirates, Egypt, Saudi Arabia, Turkey, Ukraine and South Africa, as well as several other countries. It is anticipated that a number of employees, primarily sales and marketing professionals supporting the portfolio, will transition to Acino at closing.

Additionally, both parties will enter into a multi-year manufacturing and supply agreement, under which Takeda will continue to manufacture the products on behalf of Acino.

Acino agreed to acquire the assets from Takeda for a total value in excess of $200m. The acquisition is subject to approvals by the relevant authorities and is expected to close during January - March 2020. Acino was advised by Rothschild & Co (financial advisor), Latham & Watkins (legal advisor), PwC (financial consultant) and McKinsey (commercial advisor).

 

Press contact:

Acino International AG   

Sara Vermeulen-Anastasi, Head of Corporate Communications

T: +41 44 555 2209           

             

About Acino

Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, the CIS Region, and Latin America. The company is backed by Nordic Capital and Avista. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. With a proven track-record and in-depth knowledge of our markets, our dedication to get medication to those who need it most, and with a scientific educational approach, we aim to become the preferred brand for patients and professionals. When you choose Acino, you are choosing quality you can rely on. For more information: www.acino.swiss